Abeona Therapeutics Inc. Common Stock

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. The company is headquartered in Cleveland, Ohio and currently employs 136 full-time employees. The Company’s lead clinical program is pz-cel, autologous, COL7A1 gene-corrected epidermal sheets, an investigational product in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.